Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?

Life Sciences

Volumn 75, Issue 10, 2004, Pages 1205-1210

  Mueck, A O ^a   Seeger, H ^a   Huober, J ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

2 Methoxyestradiol; Breast cancer cells; Chemotherapeutics; Proliferation

Indexed keywords

2 METHOXYESTRADIOL; CARBOPLATIN; DAUNORUBICIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; LETROZOLE; MAFOSFAMIDE; NAVELBINE; PACLITAXEL; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESTRADIOL; FEMALE; HUMANS;

MINK CELL FOCUS-FORMING VIRUS;

EID: 3042693945     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2004.02.023     Document Type: Article

References (14)

1. Amorino G.P., Freeman M.L., Choy H. Enhancement of radiation effects in vitro by the estrogen metabolite 2-methoxyestradiol. Radiation and Research. 153:2000;384-391
2. Andreotti P.E., Thornthwaite J.T., Morse I.S. ATP tumor chemosensitivity assay. Stanley R., Kricka L.J. Bioluminescence and Chemiluminescence: Current Status. 1991;417-420 Wiley, Chichester
3. Bentrem D.J., Jordan V.C. Role of antiestrogens and aromatase inhibitors in breast cancer treatment. Current Opinion in Obstetrics and Gynecology. 14:2002;5-12
4. Dubey R.K., Jackson E.K. Cardiovascular protective effects of 17β-estradiol metabolites. Journal of Applied Physiology. 91:2001;1868-1883
5. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and supresses tumour growth. Nature. 368:1994;237-239
6. Leonard R.C.F., Rodger A., Dixon J.M. Metastatic breast cancer. British Medical Journal. 309:1994;1501-1504
7. Lippert C., Seeger H., Mueck A.O. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sciences. 2003:2003;877-883
8. Lippert C., Seeger H., Mueck A.O., Lippert T.H. The effects of A-ring and D-ring metabolites of estradiol on the proliferation of vascular endothelial cells. Life Sciences. 67:2000;1653-1658
9. Miller K.D., Haney L.G., Pribluda V.S., Sledge G.W. A phase II safety, pharmacokinetic and pharmacodynamic study of Panzem (2-methoxyestraidol) in patients with refractory metastatic breast cancer. 37th Congress of the American Society of Clinical Oncology, San Francisco, May 12-15:2001;. Abstract no. 170
10. Purohit A., Singh A., Ghilchik M.W., Reed M.J. Inhibition of tumor necrosis factor α-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochemical and Biophyical Research Community. 261:1999;214-221
11. Santen R.J. Inhibition of aromatase: insights from recent studies. Steroids. 68:2003;559-567
12. Seeger H., Mueck A.O., Lippert T.H. Effect of estradiol metabolites on the susceptibility of low density lipoprotein to oxidation. Life Sciences. 61:1997;856-868
13. Seeger H., Mueck A.O., Lippert T.H. Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sciences. 65:1999;167-170
14. Zhu B.T., Connery A.H. Is 2-methoxyestradiol an endogenous metabolite that inhibits mammary carcinogenesis? Cancer Research. 58:1998;2269-2277